Join Growin Stock Community!
Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

PFE Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q1'26, Pfizer's cash and short-term investments stood at $13.1B USD, reflecting a modest decline from $13.6B USD in Q4'25, while total debt was reported at $64.5B USD, down slightly from $64.8B USD in the prior quarter. This latest data point indicates a net debt position of approximately $51.4B USD, maintaining a stable but elevated leverage level for the pharmaceutical giant. Over the period from Q2'23 to Q1'26, cash and short-term investments exhibited a sharp downward trend, plummeting from $44.8B USD to $13.1B USD, with a notable inflection point in Q4'23 when it dropped to $12.7B USD before partial recoveries in Q4'24 ($20.5B USD) and subsequent declines. In contrast, debt showed relative stability with a gradual reduction from $65.3B USD to $64.5B USD, interrupted by a peak of $71.9B USD in Q4'23, underscoring improved debt management amid persistent cash erosion that could signal tighter liquidity pressures ahead.